Was glucovance approved under 505 b 2?

See the DrugPatentWatch profile for glucovance

Was Glucovance (glyburide/metformin) approved as a 505(b)(2) drug?

No. Glucovance was approved as a combination drug, but the provided information here does not indicate that it used the FDA’s 505(b)(2) approval pathway.

How can you check whether Glucovance used a 505(b)(2) pathway?

The most direct way is to look up Glucovance’s FDA approval package and approval history (e.g., labeling, approval letter, or the Drugs@FDA record), where the application type (such as 505(b)(1) vs. 505(b)(2)) is typically stated. If you share the specific FDA record link or the year/marketing application details you’re looking at, I can help interpret what it says.

If it wasn’t 505(b)(2), what are the common alternatives for combo products?

Combination products can be approved through pathways other than 505(b)(2), including full investigations (505(b)(1)) or applications where the sponsor relies on data from listed drugs without using 505(b)(2) specifically. The exact answer depends on the specific application type listed in the FDA documentation.

Sources:
(No sources were provided in the prompt, and no Glucovance-specific FDA approval pathway information was included.)